Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8124976 | 0.94 | MMP1 (0.49) | PGRALDH1A1HTTMAPK1CYP3A4 | |
| Diphenylether SCHEMBL4640253 | 0.92 | PGR (0.64) | PGRALDH1A1HTTMMP1CA1 | |
| SCHEMBL9720036 | 0.91 | HTT (0.58) | PGRALDH1A1HTTMAPK1SOS1 | |
| SCHEMBL433497 | 0.91 | HTT (0.58) | PGRALDH1A1HTTMAPK1SOS1 | |
| SCHEMBL67558 | 0.86 | ALDH1A1 (0.65) | ALDH1A1MAPK1CYP3A4MMP1CA1 | |
| SCHEMBL4829227 | 0.86 | PGR (0.47) | PGRALDH1A1HTTMAPK1MMP1 | |
| SCHEMBL10396881 | 0.84 | ALDH1A1 (0.73) | PGRALDH1A1HTTMAPK1CYP3A4 | |
| SCHEMBL809432 | 0.84 | ALDH1A1 (0.73) | PGRALDH1A1HTTMAPK1CYP3A4 | |
| SCHEMBL4374736 | 0.84 | ALDH1A1 (0.73) | PGRALDH1A1HTTMAPK1CYP3A4 | |
| SCHEMBL822784 | 0.84 | ALDH1A1 (0.73) | PGRALDH1A1HTTMAPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524194-B2 | Radiolabelled MMP selective compounds | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2013-09-03 | — | — | US | disclosed |
| US-20110171133-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2011-07-14 | — | — | US | disclosed |
| EP-2285759-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) | 2011-02-23 | — | — | EP | disclosed |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-7803793-B2 | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-28 | — | — | US | disclosed |
| WO-2010039911-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009139633-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009139634-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2009-11-19 | — | — | WO | disclosed |
| EP-2119690-A1 | Radiolabelled MMP selective compounds | Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) | 2009-11-18 | — | — | EP | disclosed |
| EP-2089365-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-08-19 | — | — | EP | disclosed |
| CN-1207734-A | Metalloprotease inhibitors, pharmaceutical compositions containing them and their use as medicaments, process and intermediates for their preparation | AGOURON PHARMA (US) | 1999-02-10 | — | — | CN | disclosed |
| WO-1998050348-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0874830-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998043963-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES | AGOURON PHARMACEUTICALS, INC. (US) | 1998-10-08 | — | — | WO | disclosed |
| EP-0861236-A1 | CYCLIC AND HETEROCYCLIC N-SUBSTITUTED ALPHA-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-09-02 | — | — | EP | disclosed |
| WO-1998033768-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| US-5753653-A | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | AGOURON PHARMACEUTICALS, INC. (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1997020824-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-12 | — | — | WO | disclosed |
| WO-1997018194-A1 | CYCLIC AND HETEROCYCLIC N-SUBSTITUTED α-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-22 | — | — | WO | disclosed |
| US-4517354-A | PROTECTIVE COATINGS | PLASTICS ENGINEERING COMPANY (US) | 1985-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | PGR 2020/4885ALDH1A1 530/4885HTT 1950/4885 |
| US-20110171133-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | MMP1, MMP3, MMP9 | PGR 1866/4885ALDH1A1 1458/4885HTT 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.